Patent · US Active

1, 3, 4-oxadiazol-2-ones as PPAR delta modulators and their use thereof

US7872032B2 · kind B2 · utility

0Cited by

3References

4Claims

0Family size

Assignees

Aventis Pharmaceuticals Inc. · US
Sanofi-Aventis Deutschland GMBH · DE

Inventors

Daniel McGarry · King of Prussia, US
Jochen Goerlitzer · Frankfurt am Main, DE
Stefanie Keil · Frankfurt am Main, DE
Karen Chandross · Somerville, US
Jean Merrill · Morristown, US
Wolfgang Wendler · Bad Camberg, DE

Key dates

Filing date	Jul 20, 2009
Grant date	Jan 18, 2011
Priority date	—
Expiry date	Jul 20, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D277/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to 1,3,4-oxadiazalones, compounds of formula I and their pharmaceutically acceptable salts stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein.The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.